에 대한 최신 뉴스 Tenon Medical (NASDAQ:TNON) 주식

Tenon Medical

Tenon Medical Inc is a medical device company that has developed a novel, minimally invasive approach to the sacroiliac joint (the SI Joint) using a single, robust, titanium implant for the treatment of the common types of SI Joint disorders that cause lower back pain. The Company is focused on three commercial opportunities: 1) Primary SI Joint procedures, 2) Revision procedures of failed SI Joint implants, and 3) SI Joint fusion adjunct to a spine fusion construct. The company derives the majority of its revenue from sales of The Catamaran System to a limited number of clinicians.

Exclusives

Trading Ideas

AAPL

AMZN

APLD

CNEY

GLMD

GOVX

IMRX

INTC

LUMN

LUNR

NDRA

NVDA

PLTR

SMCI

SMMT

TNON

TSLA

WHLR

매일 거래일마다 벤징가 프로(Benzinga Pro)에서 수백 개의 헤드라인과 보도자료가 올라온다. 이는 트레이더들이 전체 시장 및 개별 종목에 대한 최신 뉴스를 확인할 수 있는 소스이다. 2024년 9월에 Benzinga Pro에서 가장 많이 검색된 주식들을 살펴보겠다. 현재 가격과 연초 대비 성과는 9월 30일 기준이며 배당금은 포함되지 않았다.

독점: 9월 벤징가 프로에서 가장 많이 검색된 상위 20개 티커 - 테슬라, 엔비디아, 애플은 어디에?

Biotech

REIT

Health Care

Stock Split

Tech

Real Estate

EQIX

NVAX

ORCL

매주 ‘벤징가의 스톡 위스퍼 지수(Benzinga&#39;s Stock Whisper Index)&#39;는 독점 데이터(proprietary data)와 패턴 인식의 조합을 사용하여 표면 바로 아래에서 주목을 끌고 있는 주식 5종목을 소개한다.

벤징가의 &#39;스톡 위스퍼&#39; 지수: 투자자들이 몰래 주시하지만 아직 말하지 않는 주식 5종목

Tenon Medical Inc

WIIM

Kroger shares are trading lower following mixed Q4 financial results and FY25 guidance with a midpoint below estimates.

Needham analyst Charles Shi reiterates Ultra Clean Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UCTT#NASDAQ">UCTT</a>) with a Buy and maintains $40 price target.

News

Price Target

Reiteration

Analyst Ratings

UCTT

Needham Reiterates Buy on Ultra Clean Hldgs, Maintains $40 Price Target

Guidance

Kroger Sees FY25 Adj. EPS $4.60-$4.80 vs $4.79 Est., Sees FY25 Identical Sales Growth Without Fuel 2.0%-3.0%

7 analysts have shared their evaluations of Yext (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/YEXT#NYSE">YEXT</a>) during the recent three months, expressing a mix of bullish and bearish perspectives.
Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">6</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $9.64, a high estimate of $10.50, and a low estimate of $7.50. Marking an increase of 9.3%, the current average surpasses the previous average price target of $8.82. 
<img src="https://www.benzinga.com/files/images/story/2025/1741266130_0.png" alt="price target chart" />
<h2>Analyzing Analyst Ratings: A Detailed Breakdown</h2>
The analysis of recent analyst actions sheds light on the perception of Yext by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ryan MacDonald</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$10.00</td>
<td>$10.00</td>
</tr>
<tr>
<td>Rohit Kulkarni</td>
<td>Roth MKM</td>
<td>Lowers</td>
<td>Buy</td>
<td>$9.50</td>
<td>$10.50</td>
</tr>
<tr>
<td>Ryan MacDonald</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$10.00</td>
<td>$10.00</td>
</tr>
<tr>
<td>Ryan MacDonald</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$10.00</td>
<td>$10.00</td>
</tr>
<tr>
<td>Rohit Kulkarni</td>
<td>Roth MKM</td>
<td>Raises</td>
<td>Buy</td>
<td>$10.50</td>
<td>$7.50</td>
</tr>
<tr>
<td>Tom White</td>
<td>DA Davidson</td>
<td>Raises</td>
<td>Neutral</td>
<td>$7.50</td>
<td>$5.75</td>
</tr>
<tr>
<td>Ryan MacDonald</td>
<td>Needham</td>
<td>Raises</td>
<td>Buy</td>
<td>$10.00</td>
<td>$8.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Yext. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Providing a comprehensive analysis, analysts offer qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Yext compared to the broader market.</li>
<li>Price Targets: Delving into movements, analysts provide estimates for the future value of Yext's stock. This analysis reveals shifts in analysts' expectations over time.</li>
</ul>
Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of Yext's market position. Stay informed and make well-informed decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/YEXT/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Yext analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">you can start by tracking it here</a>.
<h2>Discovering Yext: A Closer Look</h2>
Yext Inc provides a knowledge engine platform that lets businesses manage their digital knowledge in the cloud and sync it to approximately 200 services including Apple Maps, Bing, Cortana, Facebook, Google, Google Maps, Instagram, Siri and Yelp. Digital knowledge is the structured information that a business wants to make publicly accessible. The company also makes search intelligent by helping to provide precise, accurate and current answers to location-based queries that are conducted across the web and mobile applications and voice and artificial intelligence, or AI, engines. The company derives the majority of its revenues from subscription services. Geographically, the company generates a majority of its revenue from North America and the rest from International markets.
<h3>Yext: Delving into Financials</h3>
Market Capitalization: With restricted market capitalization, the company is positioned below industry averages. This reflects a smaller scale relative to peers.
Revenue Growth: Yext's revenue growth over a period of 3 months has been noteworthy. As of 31 October, 2024, the company achieved a revenue growth rate of approximately 12.68%. This indicates a substantial increase in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Information Technology sector.
Net Margin: Yext's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of -11.23%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): Yext's ROE is below industry standards, pointing towards difficulties in efficiently utilizing equity capital. With an ROE of -7.93%, the company may encounter challenges in delivering satisfactory returns for shareholders.
Return on Assets (ROA): The company's ROA is below industry benchmarks, signaling potential difficulties in efficiently utilizing assets. With an ROA of -2.56%, the company may need to address challenges in generating satisfactory returns from its assets.
Debt Management: With a below-average debt-to-equity ratio of 0.62, Yext adopts a prudent financial strategy, indicating a balanced approach to debt management.
<h2>The Basics of Analyst Ratings</h2>
Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter. 
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

YEXT

Analyst Expectations For Yext's Future

Earnings

Earnings Misses

VRME

VerifyMe Q4 2024 GAAP EPS $(0.05) Misses $(0.04) Estimate, Sales $7.661M Miss $8.213M Estimate

Cracker Barrel Old (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CBRL#NASDAQ">CBRL</a>) reported quarterly earnings of $1.38 per share which beat the analyst consensus estimate of $1.00 by 38 percent. The company reported quarterly sales of $949.44 million which beat the analyst consensus estimate of $943.58 million by 0.62 percent. This is a 1.50 percent increase over sales of $935.40 million the same period last year.

Earnings Beats

CBRL

Cracker Barrel Old Q2 2025 Adj EPS $1.38 Beats $1.00 Estimate, Sales $949.44M Beat $943.58M Estimate

Delcath Systems (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DCTH#NASDAQ">DCTH</a>) reported quarterly losses of $(0.11) per share which missed the analyst consensus estimate of $(0.02) by 450 percent. This is a 77.08 percent increase over losses of $(0.48) per share from the same period last year. The company reported quarterly sales of $15.10 million which beat the analyst consensus estimate of $13.78 million by 9.58 percent. This is a 2.70K percent increase over sales of $539.00 thousand the same period last year.

DCTH

Delcath Systems Q4 2024 GAAP EPS $(0.11) Misses $(0.02) Estimate, Sales $15.10M Beat $13.78M Estimate

Providing a diverse range of perspectives from bullish to bearish, 11 analysts have published ratings on Marvell Tech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRVL#NASDAQ">MRVL</a>) in the last three months.
The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">6</td>
<td align="right">3</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">3</td>
<td align="right">3</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts have set 12-month price targets for Marvell Tech, revealing an average target of $131.18, a high estimate of $150.00, and a low estimate of $100.00. This upward trend is evident, with the current average reflecting a 6.18% increase from the previous average price target of $123.55.
<img src="https://www.benzinga.com/files/images/story/2025/1741266063_0.png" alt="price target chart" />
<h2>Investigating Analyst Ratings: An Elaborate Study</h2>
An in-depth analysis of recent analyst actions unveils how financial experts perceive Marvell Tech. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cody Acree</td>
<td>Benchmark</td>
<td>Maintains</td>
<td>Buy</td>
<td>$135.00</td>
<td>$135.00</td>
</tr>
<tr>
<td>Kevin Cassidy</td>
<td>Rosenblatt</td>
<td>Maintains</td>
<td>Buy</td>
<td>$140.00</td>
<td>$140.00</td>
</tr>
<tr>
<td>Quinn Bolton</td>
<td>Needham</td>
<td>Lowers</td>
<td>Buy</td>
<td>$100.00</td>
<td>$120.00</td>
</tr>
<tr>
<td>Joseph Moore</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$113.00</td>
<td>$120.00</td>
</tr>
<tr>
<td>John Vinh</td>
<td>Keybanc</td>
<td>Raises</td>
<td>Overweight</td>
<td>$135.00</td>
<td>$125.00</td>
</tr>
<tr>
<td>Blayne Curtis</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$150.00</td>
<td>$115.00</td>
</tr>
<tr>
<td>Aaron Rakers</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$140.00</td>
<td>$130.00</td>
</tr>
<tr>
<td>Toshiya Hari</td>
<td>Goldman Sachs</td>
<td>Raises</td>
<td>Buy</td>
<td>$131.00</td>
<td>$115.00</td>
</tr>
<tr>
<td>Christian Schwab</td>
<td>Craig-Hallum</td>
<td>Raises</td>
<td>Buy</td>
<td>$149.00</td>
<td>$132.00</td>
</tr>
<tr>
<td>Tore Svanberg</td>
<td>Stifel</td>
<td>Raises</td>
<td>Buy</td>
<td>$130.00</td>
<td>$125.00</td>
</tr>
<tr>
<td>Joseph Moore</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$120.00</td>
<td>$102.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Marvell Tech. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey the analysts' expectations for the relative performance of Marvell Tech compared to the broader market.</li>
<li>Price Targets: Analysts set price targets as an estimate of a stock's future value. Comparing the current and prior price targets provides insight into how analysts' expectations have changed over time. This information can be valuable for investors seeking to understand consensus views on the stock's potential future performance.</li>
</ul>
Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of Marvell Tech's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/MRVL/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Marvell Tech analyst ratings.</a>
<h2>Discovering Marvell Tech: A Closer Look</h2>
Marvell Technology is a fabless chip designer focused on wired networking, where it has the second-highest market share. Marvell serves the data center, carrier, enterprise, automotive, and consumer end markets with processors, optical and copper transceivers, switches, and storage controllers.
<h3>Marvell Tech's Financial Performance</h3>
Market Capitalization: With restricted market capitalization, the company is positioned below industry averages. This reflects a smaller scale relative to peers.
Revenue Growth: Marvell Tech displayed positive results in 3 months. As of 31 October, 2024, the company achieved a solid revenue growth rate of approximately 6.87%. This indicates a notable increase in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Information Technology sector.
Net Margin: Marvell Tech's net margin falls below industry averages, indicating challenges in achieving strong profitability. With a net margin of -44.61%, the company may face hurdles in effective cost management.
Return on Equity (ROE): Marvell Tech's ROE falls below industry averages, indicating challenges in efficiently using equity capital. With an ROE of -4.9%, the company may face hurdles in generating optimal returns for shareholders.
Return on Assets (ROA): The company's ROA is below industry benchmarks, signaling potential difficulties in efficiently utilizing assets. With an ROA of -3.38%, the company may need to address challenges in generating satisfactory returns from its assets.
Debt Management: Marvell Tech's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.32.
<h2>The Basics of Analyst Ratings</h2>
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

MRVL

Forecasting The Future: 11 Analyst Projections For Marvell Tech

Seanergy Maritime Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SHIP#NASDAQ">SHIP</a>) reported quarterly earnings of $0.34 per share which beat the analyst consensus estimate of $0.21 by 61.9 percent. This is a 41.38 percent decrease over earnings of $0.58 per share from the same period last year. The company reported quarterly sales of $41.68 million which beat the analyst consensus estimate of $39.83 million by 4.64 percent. This is a 5.70 percent increase over sales of $39.43 million the same period last year.

SHIP

Seanergy Maritime Hldgs Q4 Adj EPS $0.34 Beats $0.21 Estimate, Sales $41.68M Beat $39.83M Estimate

In the last three months, 9 analysts have published ratings on Veeva Systems (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VEEV#NYSE">VEEV</a>), offering a diverse range of perspectives from bullish to bearish.
The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">3</td>
<td align="right">2</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">1</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">1</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts have set 12-month price targets for Veeva Systems, revealing an average target of $245.0, a high estimate of $307.00, and a low estimate of $195.00. Experiencing a 3.88% decline, the current average is now lower than the previous average price target of $254.89. 
<img src="https://www.benzinga.com/files/images/story/2025/1741266044_0.png" alt="price target chart" />
<h2>Decoding Analyst Ratings: A Detailed Look</h2>
An in-depth analysis of recent analyst actions unveils how financial experts perceive Veeva Systems. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ryan MacDonald</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$270.00</td>
<td>$270.00</td>
</tr>
<tr>
<td>Gabriela Borges</td>
<td>Goldman Sachs</td>
<td>Lowers</td>
<td>Sell</td>
<td>$200.00</td>
<td>$261.00</td>
</tr>
<tr>
<td>Ryan MacDonald</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$270.00</td>
<td>$270.00</td>
</tr>
<tr>
<td>Jailendra Singh</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Hold</td>
<td>$210.00</td>
<td>$261.00</td>
</tr>
<tr>
<td>Scott Schoenhaus</td>
<td>Keybanc</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$255.00</td>
<td>$285.00</td>
</tr>
<tr>
<td>Craig Hettenbach</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Underweight</td>
<td>$195.00</td>
<td>$183.00</td>
</tr>
<tr>
<td>Anne Samuel</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Neutral</td>
<td>$218.00</td>
<td>$208.00</td>
</tr>
<tr>
<td>Tyler Radke</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Buy</td>
<td>$307.00</td>
<td>$281.00</td>
</tr>
<tr>
<td>Steven Valiquette</td>
<td>Mizuho</td>
<td>Raises</td>
<td>Outperform</td>
<td>$280.00</td>
<td>$275.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Veeva Systems. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analyzing trends, analysts offer qualitative evaluations, ranging from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Veeva Systems compared to the broader market.</li>
<li>Price Targets: Gaining insights, analysts provide estimates for the future value of Veeva Systems's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of Veeva Systems's market standing. Stay informed and make data-driven decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/VEEV/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Veeva Systems analyst ratings.</a>
<h2>Get to Know Veeva Systems Better</h2>
Veeva is the global leading supplier of cloud-based software solutions for the life sciences industry. The company's best-of-breed offerings address operating and regulatory requirements for customers ranging from small, emerging biotechnology companies to departments of global pharmaceutical manufacturers. The company leverages its domain expertise to improve the efficiency and compliance of the underserved life sciences industry, displacing large, highly customized and dated enterprise resource planning systems that have limited flexibility. Its two main products are Veeva CRM, a customer relationship management platform for companies with a salesforce, and Veeva Vault, a content management platform that tackles various functions within any life sciences company.
<h3>Veeva Systems's Economic Impact: An Analysis</h3>
Market Capitalization Analysis: The company's market capitalization surpasses industry averages, showcasing a dominant size relative to peers and suggesting a strong market position.
Revenue Growth: Over the 3 months period, Veeva Systems showcased positive performance, achieving a revenue growth rate of 13.41% as of 31 October, 2024. This reflects a substantial increase in the company's top-line earnings. When compared to others in the Health Care sector, the company excelled with a growth rate higher than the average among peers.
Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of 26.57%, the company showcases strong profitability and effective cost control.
Return on Equity (ROE): Veeva Systems's ROE stands out, surpassing industry averages. With an impressive ROE of 3.48%, the company demonstrates effective use of equity capital and strong financial performance.
Return on Assets (ROA): Veeva Systems's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of 2.91%, the company showcases efficient use of assets and strong financial health.
Debt Management: Veeva Systems's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.01.
<h2>The Significance of Analyst Ratings Explained</h2>
Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.
Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

VEEV

Beyond The Numbers: 9 Analysts Discuss Veeva Systems Stock

Kroger Q4 2024 Adj. EPS $1.14 Beats $1.11 Estimate, Sales $34.308B Miss $34.509B Estimate

John Wiley & Sons Q3 2025 Adj. EPS $0.84 Beats $0.65 Estimate, Sales $404.626M Beat $401.100M Estimate

Fartcoin (CRYPTO: FARTCOIN), one of Solana's (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/sol/usd">SOL</a>) leading meme coins, is making waves with a 16% single-day gain. As excitement builds for the <a href="https://www.benzinga.com/trading-ideas/movers/25/03/44157693/bitcoin-ethereum-dogecoin-spike-amid-high-hopes-from-white-house-crypto-summit-this-analyst-has-some-good-news-for-those-patiently-holding-their-eth">upcoming crypto summit</a>, traders speculate that the meme coin market could see another explosive run.
What Happened: Prominent trader Unipcs <a href="https://x.com/theunipcs/status/1897049695052288325">pointed</a> out that Fartcoin is still down 92% from its $2.7 billion all-time high last month but maintains strong mindshare in the meme coin space. 
Seeing this as a high-risk/high-reward opportunity, he has taken a sizeable low-leverage position in anticipation of a bull run.
Altcoin Sherpa echoed the same view, stating that mindshare is crucial for meme coins. If Fartcoin holds its current range and consolidates, it could set up for another leg higher.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">I feel like FARTCOIN still has a lot of mindshare despite being down so much. I still have a bag and I think this area is a decent one overall for consolidation/support. Let&#39;s see what happens <a href="https://t.co/thbD8Alw5A">pic.twitter.com/thbD8Alw5A</a>
&mdash; Altcoin Sherpa (@AltcoinSherpa) <a href="https://twitter.com/AltcoinSherpa/status/1897604970888810841?ref_src=twsrc%5Etfw">March 6, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Cold Blooded Shiller <a href="https://x.com/ColdBloodShill/status/1897567002673205690">noted</a> that a confirmed 12-hour bullish divergence could trigger a strong bounce, while crypto trader Doc <a href="https://x.com/jkrdoc/status/1897421272708972889">took</a> it a step further, calling Fartcoin a leveraged play for the entire bull cycle, declaring: &#8220;Being a bull = believing in Fartcoin.&#8221;
In an X post on Wednesday, ElonMoney <a href="https://x.com/0xelonmoney/status/1897191419728814228">cited</a> Nansen data, showing that Fartcoin received the highest net inflow from smart money in the past 24 hours.
Also Read: <a href="https://www.benzinga.com/markets/cryptocurrency/25/02/43636904/anthony-scaramucci-warns-meme-coins-create-market-contagion-fuel-bitcoin-skepticism">Anthony Scaramucci Warns Meme Coins Create Market Contagion, Fuel Bitcoin Skepticism</a>
What's Next: According to CoinGecko, Fartcoin now leads all meme coins with 16.3% daily gains, and ranks fifth in trading volume at $194.9 million, signaling growing interest.
Trump's recent announcement of a U.S. crypto reserve, which includes Solana alongside Bitcoin, Ethereum, XRP, and Cardano, could further drive demand for Solana-based meme coins like Fartcoin.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/25/02/43670741/forget-dogecoin-shiba-inu-ai-crypto-coins-may-lead-the-meme-coin-rebound">Forget Dogecoin, Shiba Inu, AI Crypto Coins May Lead The Meme Coin Rebound</a></li>
</ul>
Image: Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

$SOL

Fartcoin Surges 16% In A Day, Outpacing Dogecoin, Shiba Inu As Trump Crypto Summit Anticipation Builds

JP Morgan analyst Matthew Boss maintains Victoria's Secret (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VSCO#NYSE">VSCO</a>) with a Neutral and lowers the price target from $43 to $35.

VSCO

JP Morgan Maintains Neutral on Victoria's Secret, Lowers Price Target to $35

Macy&#8217;s&nbsp;Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/M#NYSE">M</a>) shares are <a target="_blank" href="https://www.benzinga.com/premarket" rel="noreferrer noopener">trading lower in premarket</a> on Thursday after the fourth-quarter earnings.
The company reported a fourth-quarter sales decline of 4.3% year-on-year to $7.768 billion, missing the <a href="https://www.benzinga.com/pressreleases/25/03/b44161902/macys-inc-reports-fourth-quarter-and-fiscal-year-2024-results" target="_blank" rel="noreferrer noopener">analyst consensus of $7.867 billion.</a>
Comparable sales decreased 1.1% on an owned basis and up&nbsp;0.2%&nbsp;on an owned-plus-licensed-plus-marketplace basis.
The company&#8217;s go-forward business&nbsp;comparable sales were down&nbsp;0.7%&nbsp;on an owned basis and up&nbsp;0.6%&nbsp;on an owned-plus-licensed-plus-marketplace basis.&nbsp;
By nameplate, Macy&#8217;s net sales were down&nbsp;5.3%, with comparable sales down&nbsp;1.9%&nbsp;on an owned basis and down&nbsp;0.9%&nbsp;on an owned-plus-licensed-plus-marketplace basis.
Bloomingdale&#8217;s net sales were up 2.0%, with comparable sales up 4.8% on an owned basis and up 6.5% on an owned-plus-licensed-plus-marketplace basis. Bluemercury net sales rose 2.4%, and comparable sales grew 6.2% on an owned basis.
The operating margin was 6.2%. Operating income for the quarter was $500 million compared to a loss of $149 million last year.
The gross margin was 35.7%, down 80 basis points from the prior year. Adjusted EBITDA was $903 million versus $1.09 billion last year. Adjusted EPS of $1.80 <a target="_blank" href="https://www.benzinga.com/earnings" rel="noreferrer noopener">beat the consensus estimate of $1.53.</a>
Also Read: <a target="_blank" href="https://www.benzinga.com/analyst-ratings/analyst-color/25/03/44147956/ross-stores-faces-slower-growth-with-shifts-in-lower-income-customers-preference-says-analyst" rel="noreferrer noopener">Ross Stores Faces Slower Growth With Shifts In Lower-Income Customers Preference, Says Analyst</a>
Macy&#8217;s&nbsp;held $1.3 billion in cash and equivalents&nbsp;as of February 1.&nbsp;Operating cash flow for twelve months totaled $1.3 billion with a free cash flow of $679 million.
Merchandise inventories were up 2.5%&nbsp;year-over-year. As of the end of FY24, total debt was $2.8 billion.
&#8220;As we close out the first year of the Bold New Chapter strategy, investments in the customer experience enabled us to achieve our highest comparable sales of the year, our best performance in 11 quarters,&#8221; said&nbsp;chairman&nbsp;and CEO Tony Spring.
Outlook: Macy&#8217;s expects FY25 revenue of $21.0 billion – $21.4 billion, against the consensus of $21.811 billion. The company sees FY25 adjusted EPS of $2.05 &#8211; $2.25 against the estimate of $2.31.
Macy&#8217;s&nbsp;currently sees FY25 comparable owned-plus-licensed-plus-marketplace sales <a target="_blank" href="https://www.benzinga.com/calendars/guidance" rel="noreferrer noopener">of -2% to -0.5%.</a>
Price Action: M shares traded lower by 4.13% at $12.76 at last check Thursday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/tech/25/03/44143576/apples-latest-macbook-air-with-m4-chip-is-twice-as-fast-as-its-predecessor-with-lower-price" target="_blank" rel="noreferrer noopener">Apple&#8217;s Latest MacBook Air With M4 Chip Is Twice As Fast As Its Predecessor With Lower Price</a></li>
</ul>
Photo via Shutterstock.

Equities

Movers

General

Macy's Q4 Revenue Lag And Annual Outlook Disappoints Investors, Stock Slides

JP Morgan analyst Ken Goldman maintains Conagra Brands (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CAG#NYSE">CAG</a>) with a Neutral and lowers the price target from $29 to $26.

JP Morgan Maintains Neutral on Conagra Brands, Lowers Price Target to $26

Hippo Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HIPO#NYSE">HIPO</a>) sees FY2025 sales of $420.000 million-$450.000 million vs $450.04 million analyst estimate.

HIPO

Hippo Holdings Sees FY2025 Sales $420.000M-$450.000M vs $450.04M Est

Contracts

Jacobs Awarded Operational Technology Cybersecurity Contract, Valued At $13.4M, With Hampton Roads Sanitation District

Benchmark analyst Cody Acree reiterates Marvell Tech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRVL#NASDAQ">MRVL</a>) with a Buy and maintains $135 price target.

Benchmark Reiterates Buy on Marvell Tech, Maintains $135 Price Target

JP Morgan analyst Karen Li upgrades Full Truck Alliance Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/YMM#NYSE">YMM</a>) from Neutral to Overweight and raises the price target from $13 to $18.

Upgrades

JP Morgan Upgrades Full Truck Alliance Co to Overweight, Raises Price Target to $18

Press Releases

Tenon Medical, Inc. Announces Pricing of $4.5 Million Public Offering Priced At-The-Market Under Nasdaq Rules

Tenon Medical, Inc. Announces Closing of $4.5 Million Public Offering Priced At-The-Market Under Nasdaq Rules

Tenon Medical Announces Issuance of Three Notices of Allowance for Patent Applications from the USPTO

Tenon Medical(R) Announces Issuance of Three U.S. Patents

Tenon Medical(R) Regains Full Compliance with Nasdaq Continued Listing Requirements

Tenon Medical, Inc. Announces Timing of Third Quarter 2024 Financial Results

Tenon Medical Announces Initial Clinical Cases Successfully Completed with Company's New Catamaran(R) SE SI Joint Fusion System

"The Future is Bright: Peraso Inc. (NASDAQ: PRSO) Expands Technology for Tactical Applications in High-Demand Industries – More Stocks Inside…"

Tenon Medical Reports Third Quarter 2024 Financial Results

Tenon Medical(R) to Host Meetings During the 2025 J.P. Morgan Healthcare Conference in San Francisco

AVTE

EVGN

ILLR

PRSO

Aethlon Medical

Autonomix Medical

Aspira Women's Health Inc. - Common Stock

Aspira Womens Health

Bluejay Diagnostics

Cutera

Ekso Bionics Holdings, Inc. - Common Stock

Ekso Bionics Holdings

GlucoTrack

HeartSciences

Helius Medical Technologies, Inc. - Class A Common Stock

Helius Medical Tech

SeaStar Medical Holding Corporation - Common Stock

SeaStar Medical Holding

Know Labs

NanoVibronix

NAYA Biosciences

ENDRA Life Sciences

NeuroMetrix

Nuwellis

PAVmed

Predictive Oncology

ReShape Lifesciences, Inc. - Common Stock

Reshape Lifesciences

SINTX Techs

Strata Skin Sciences, Inc. - Common Stock

Strata Skin Sciences

Tivic Health Systems, Inc. - Common stock

Tivic Health Systems

Venus Concept

Catheter Precision

Xylo Technologies Ltd. - American Depositary Shares

Xylo Technologies

Maxim Group

Benchmark

매일 거래일마다 벤징가 프로(Benzinga Pro)에서 수백 개의 헤드라인과 보도자료가 올라온다. 이는 트레이더들이 전체 시장 및 <a href="https://www.benzinga.com/pro/?utm_source=BZprocontent100224&amp;t=be2bearmibe3na1" target="_blank" rel="noreferrer noopener" data-google-interstitial="false">개별 종목</a>에 대한 최신 뉴스를 확인할 수 있는 소스이다.
2024년 9월에 Benzinga Pro에서 가장 많이 검색된 주식들을 살펴보겠다. 현재 가격과 연초 대비 성과는 9월 30일 기준이며 배당금은 포함되지 않았다.
1. 엔비디아 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>)
<ul>
<li>현재 가격: $121.44</li>
<li>52주 최고가/최저가: $39.23 ~ $140.76</li>
<li>연초 대비 수익률: +152.1%</li>
<li><a href="https://www.benzinga.com/top-stories/24/07/39579249/exclusive-top-10-most-searched-tickers-on-benzinga-pro-in-june-where-do-nvidia-gamestop-tesla-apple" target="_blank" rel="noopener" data-google-interstitial="false">6월</a>/<a href="https://www.benzinga.com/top-stories/24/08/40119459/exclusive-top-20-most-searched-tickers-on-benzinga-pro-in-july-2024-where-do-tesla-nvidia-apple-crow" target="_blank" rel="noopener" data-google-interstitial="false">7월</a>/<a href="https://www.benzinga.com/etfs/broad-u-s-equity-etfs/24/09/40691773/exclusive-top-20-most-searched-tickers-on-benzinga-pro-in-august-2024-where-do-tesla-n" target="_blank" rel="noopener" data-google-interstitial="false">8월 </a>순위: 1위/2위/1위</li>
</ul>
2. SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>)
<ul>
<li>현재 가격: $573.76</li>
<li>52주 최고가/최저가: $409.22 ~ $574.71</li>
<li>연초 대비 수익률: +21.4%</li>
<li>6월/7월/8월 순위: 3위/3위/2위</li>
</ul>
3. 테슬라 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>)
<ul>
<li>현재 가격: $261.63</li>
<li>52주 최고가/최저가: $138.80 ~ $271.00</li>
<li>연초 대비 수익률: +5.3%</li>
<li>6월/7월/8월 순위: 4위/1위/3위</li>
</ul>
4. 애플 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>)
<ul>
<li>현재 가격: $233.00</li>
<li>52주 최고가/최저가: $164.08 ~ $237.23</li>
<li>연초 대비 수익률: +25.5%</li>
<li>6월/7월/8월 순위: 5위/7위/6위</li>
</ul>
5. 휠러 리얼 에스테이트 인베스트 트러스트 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WHLR#NASDAQ">WHLR</a>)
<ul>
<li>현재 가격: $8.09</li>
<li>52주 최고가/최저가: $2.90 ~ $1,126.80</li>
<li>연초 대비 수익률: -92.8%</li>
<li>6월/7월/8월 순위: 20위 미만</li>
</ul>
6. Invesco QQQ Trust (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>)
<ul>
<li>현재 가격: $488.07</li>
<li>52주 최고가/최저가: $342.35 ~ $503.52</li>
<li>연초 대비 수익률: +21.2%</li>
<li>6월/7월/8월 순위: 11위/11위/9위</li>
</ul>
7. 슈퍼 마이크로 컴퓨터 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMCI#NASDAQ">SMCI</a>)
<ul>
<li>현재 가격: $416.40</li>
<li>52주 최고가/최저가: $226.59 ~ $1,229.00</li>
<li>연초 대비 수익률: +45.9%</li>
<li>6월/7월/8월 순위: 10위/19위/4위</li>
</ul>
8. 갈메드 파마슈티컬스 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GLMD#NASDAQ">GLMD</a>)
<ul>
<li>현재 가격: $6.86</li>
<li>52주 최고가/최저가: $2.73 ~ $23.80</li>
<li>연초 대비 수익률: +29.9%</li>
<li>6월/7월/8월 순위: 20위 미만</li>
</ul>
9. 인텔 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INTC#NASDAQ">INTC</a>)
<ul>
<li>현재 가격: $23.46</li>
<li>52주 최고가/최저가: $18.51 ~ $51.28</li>
<li>연초 대비 수익률: -50.9%</li>
<li>6월/7월/8월 순위: 20위 미만</li>
</ul>
10. 인튜이티브 머신스 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LUNR#NASDAQ">LUNR</a>)
<ul>
<li>현재 가격: $8.05</li>
<li>52주 최고가/최저가: $2.09 ~ $13.25</li>
<li>연초 대비 수익률: +241.1%</li>
<li>6월/7월/8월 순위: 20위 미만/20위 미만/20위</li>
</ul>
순위 밖의 주식들: 다음 주식들이 2024년 9월에 Benzinga Pro에서 11위에서 20위까지 가장 많이 검색된 종목들다.
11. 서밋 테라퓨틱스 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMMT#NASDAQ">SMMT</a>)
12. 팔란티어 테크놀로지스 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PLTR#NYSE">PLTR</a>)
13. 마이크론 테크놀로지 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MU#NASDAQ">MU</a>)
14. 테논 메디컬 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TNON#NASDAQ">TNON</a>)
15. CN 에너지 그룹 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CNEY#NASDAQ">CNEY</a>)
16. 취후오 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QH#NASDAQ">QH</a>)
17. 엔드라 라이프 사이언스 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NDRA#NASDAQ">NDRA</a>):
18. 어플라이드 디지털 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APLD#NASDAQ">APLD</a>)
19. 이뮤니어링 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IMRX#NASDAQ">IMRX</a>)
20. 트럼프 미디어 앤 테크놀로지 그룹 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DJT#NASDAQ">DJT</a>)
중요성 (Why It's Important): 엔비디아는 9월 한 달 동안 Benzinga Pro에서 가장 많이 검색된 주식으로 다시 한번 선정되었다. 이 주식은 2월 이후로 매달 1위 또는 2위를 기록하고 있으며, 때때로 SPY 또는 테슬라와 교대로 1위에 올랐다.
SPDR S&amp;P 500 ETF Trust는 9월에 S&amp;P 500 추적 지수가 사상 최고치를 기록하면서 2위를 차지했다.
테슬라는 7월에 1위를 차지한 이후 두 주 연속 3위를 기록했다. 이 주식은 2024년 동안 매달 검색된 상위 4개의 주식 중 하나로 자리 잡았다.
9월의 큰 관심은 신규 진입 주식들과 순위에서 떨어진 주식들이었다.
신규 진입자로는 휠러 리얼 에스테이트, 갈메드, 인텔 및 인튜이티브가 포함되었다. 이 4개 주식 중에서 인튜이티브만이 지난 3개월 간 상위 20위에 랭크된 바 있다. 이 신규 진입자들은 모두 지난달에 주식을 크게 변동시킨 촉매제가 있었다.
11위에서 20위까지의 목록에서도 이전 달과는 모든 주식이 달랐으며 인튜이티브는 상위 10위로 올라갔고, 팔란티어는 7위에서 12위로 하락했으며 나머지 주식들은 모두 상위 20위에 신규로 진입했다.
상위 20위의 하위 주식들 중 일부는 주가가 $5 이하로 거래되는 저가 주식들이며, 이들 주식은 큰 변동성을 보이며 Benzinga 트레이더들의 관심이 증가했다.
상위 20위에 이름 인지도로 들어온 큰 회사는 트럼프 미디어 앤 테크놀로지 그룹으로, 전 대통령 도널드 트럼프가 공동 설립자이다. 이 주식은 2024년 선거 주기 동안 매우 변동성이 컸다.
상위 10위에서 떨어진 주식들은 루멘 테크놀로지스(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LUMN#NYSE">LUMN</a>), 어드밴스드 마이크로 디바이시스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMD#NASDAQ">AMD</a>), 지오백스 랩스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOVX#NASDAQ">GOVX</a>) 및 앞서 언급한 팔란티어이다.
상위 20위에서 빠진 다른 큰 이름들은 8월에 13위였던 아마존닷컴(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>)으로, 24위로 하락하여 리스트에 아슬아슬하게 들지 못했다.
메타 플랫폼스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/META#NASDAQ">META</a>)는 상위 20위에 자주 올라온 주식으로 8월에는 15위였으나 상위 20위에서 제외되었다.
전반적으로 9월에는 8월과 같은 상위 10개의 종목이 6개 있었고, 8월의 상위 20개 종목 중 8개가 포함되었다.
다음 읽기: 
<ul>
<li><a href="https://www.benzinga.com/exclusives/24/07/39603613/exclusive-top-10-most-searched-tickers-on-benzinga-pro-in-first-half-2024-where-do-nvidia-tesla-pala">독점: 2024년 상반기 가장 많이 검색된 종목 TOP 10 – 엔비디아, 테슬라, 팔란티어, 게임스탑의 순위는?</a></li>
</ul>
이미지: Shutterstock
다른 트레이더들보다 30분 일찍 독점 시장 움직임 뉴스를 받아보세요. 
Benzinga Pro의 14일 무료 체험을 통해 독점 뉴스 기사를 이용할 수 있어 수백만 명의 다른 트레이더보다 먼저 실행 가능한 거래 뉴스를 얻을 수 있습니다. <a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor" target="_blank" rel="noreferrer noopener">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

매주 ‘벤징가의 스톡 위스퍼 지수(Benzinga's Stock Whisper Index)'는 독점 데이터(proprietary data)와 패턴 인식의 조합을 사용하여 <a href="https://www.benzinga.com/topic/stock-whisper-index" target="_blank" rel="noreferrer noopener">표면 바로 아래에서 주목을 끌고</a> 있는 주식 5종목을 소개한다.
투자자들은 가치가 저평가된, 관심이 적은, 새로운 주식들을 항상 찾고 있다. 소매 트레이더들에게 제공되는 무수한 방법 중에서 방대한 양의 정보를 좁혀내어 새로운 정보를 찾아내는 것이 어려운 경우가 많다. 이 지수에는 이러한 주식들이 왜 중요한지, 투자자나 일반 독자가 이 주식들을 주목해야 하는 이유에 대한 편집 논평이 포함되어 있다.
9월 6일 주의 벤징가 스톡 위스퍼 지수의 개요:
1. 오라클 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ORCL#NYSE">ORCL</a>): 이 기술 대기업은 월요일에 있을 1분기 재무 결과 발표를 앞두고 Benzinga 독자들로부터 강한 관심을 받고 있다.
이 회사는 작년 1분기의 1.19달러에서 증가한 1.33달러의 주당 순이익(EPS)을 보고할 것으로 예상된다. <a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent090624&amp;t=be2bearmibe3na1" target="_blank" rel="noopener">Benzinga Pro</a>의 데이터에 따르면 이 회사는 7분기 연속, 그리고 지난 10분기 중 8분기 동안 분석가들의 주당 순이익 추정치를 상회했다.
분석가들은 이 회사의 1분기 매출이 작년 1분기의 129억 4천만 달러에서 증가한 132억 4천만 달러로 보고될 것으로 추정한다. 이 회사는 4분기 연속으로, 그리고 지난 10분기 중 6분기 동안 분석가들의 매출 추정치를 달성하지 못했다.
오라클은 오픈AI와의 대규모 계약을 포함해 125억 달러 이상의 가치가 있는 30개 이상의 AI 판매 계약을 체결하여 4분기에 <a href="https://www.benzinga.com/news/earnings/24/06/39280057/oracle-misses-q4-earnings-stock-surges-on-booming-ai-demand-openai-contract-partnership-with-google" target="_blank" rel="noopener" data-google-interstitial="false">AI 수요를 강조</a>했다. 오라클은 당시 구글 클라우드와의 파트너십도 발표했다.
아래 <a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent090624&amp;t=be2bearmibe3na1" target="_blank" rel="noopener">Benzinga Pro 차트</a>에서 볼 수 있듯이 오라클의 주가는 지난 5일 동안 1.05% 상승했다. 오라클 주식은 2024년 현재까지 36.28% 상승했다. 이 주식은 금요일 0.56% 하락한 141.,81달러에 마감했다.
<figure class="wp-block-image size-full"><a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent090624&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" class="wp-image-534842" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/06105358/Screenshot-162.png" sizes="(max-width: 993px) 100vw, 993px" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/06105358/Screenshot-162.png 993w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/06105358/Screenshot-162-300x152.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/06105358/Screenshot-162-768x388.png 768w" alt="" width="993" height="502" /></a></figure>
2. 노바백스 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVAX#NASDAQ">NVAX</a>): 미국 식품의약국(FDA)이 회사의 <a href="https://www.benzinga.com/general/biotech/24/09/40688052/fda-approves-novavaxs-updated-covid-vaccine-targeting-currently-circulating-variants">업데이트된 COVID-19 백신</a>에 대한 긴급 사용 승인을 승인했다는 소식이 전해지면서 이 백신 회사의 주가는 지난 5일 동안 1.48% 상승했다. 이 업데이트된 백신은 미국 질병 통제 예방 센터(CDC)의 권장 사항에 포함되어 있다.
이 백신은 미국에서 12세 이상의 사람들이 COVID-19 예방을 위해 사용할 수 있는 유일한 단백질 기반 옵션이다. 이 회사는 또한 다음 주 두 번의 회사 프레젠테이션을 앞두고 투자자들의 관심을 끌 수도 있다. 노바백스는 9월 9일 월요일과 9월 10일 화요일에 각각 H.C. 웨인라이트(Wainwright)와 베어드(Baird) 투자자 컨퍼런스에 참석할 예정이다.
노바백스의 주식은 금요일 2.68% 하락한 11.63달러에 마감되었다.
<figure class="wp-block-image size-full"><a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent090624&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" class="wp-image-534844" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/06105414/Screenshot-163.png" sizes="(max-width: 989px) 100vw, 989px" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/06105414/Screenshot-163.png 989w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/06105414/Screenshot-163-300x152.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/06105414/Screenshot-163-768x390.png 768w" alt="" width="989" height="502" /></a></figure>
읽어보세요: <a href="https://kr.benzinga.com/news/usa/stocks/%eb%8b%a8%eb%8f%85-2024%eb%85%84-8%ec%9b%94-%eb%b2%a4%ec%a7%95%ea%b0%80-%ed%94%84%eb%a1%9c%ec%97%90%ec%84%9c-%ea%b0%80%ec%9e%a5-%ea%b2%80%ec%83%89%eb%9f%89%ec%9d%b4-%eb%a7%8e%ec%95%98%eb%8d%98/" target="_blank" rel="noopener">독점: 2024년 8월 Benzinga Pro에서 가장 많이 검색된 20개 티커</a>
3. 휠러 리얼 에스테이트 인베스트먼트 트러스트 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WHLR#NASDAQ">WHLR</a>): 이 부동산 투자 신탁의 주가는 회사가 순회 법원에서 시더 리얼티(Cedar Realty) 우선주 보유자들과 관련된 집단 소송 기각을 확정했다고 <a href="https://ir.whlr.us/news-events/press-releases/detail/1088/cedar-realty-trust-and-wheeler-real-estate-investment-trust-announce-fourth-circuit-court-affirms-dismissal-of-class-action-lawsuit">발표</a>한 후 주에 500% 이상 급등했다. 휠러(Wheeler)는 2022년 8월 시더(Cedar)를 인수했으며, 이번 소송은 시더의 전 이사회와 관련된 계약 위반을 주장했다.
시더와 휠러의 CEO인 앤드류 프랭클린(Andrew Franklin)은 &#8220;이 문제가 해결되었음에도 불구하고 두 회사 모두 전략 계획을 실행할 수 있는 좋은 위치를 유지하고 있다&#8221;고 말했다.
이 회사는 14개 주를 포괄하는 북동부, 중부 대서양 및 남동부 지역에 식료품점을 중심으로 한 77개의 쇼핑 센터를 소유하고 있다. 이 회사의 소송이 해결됨으로 인해 투자자들은 긍정적인 장기 전망을 볼 수 있었다.
휠러의 주식은 금요일 147.58% 급등한 10.25달러에 마감되었다. 이후 시간외 거래에서 24.88% 하락했다.
<a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent090624&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" class="wp-image-534845" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/06105430/Screenshot-164.png" sizes="(max-width: 997px) 100vw, 997px" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/06105430/Screenshot-164.png 997w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/06105430/Screenshot-164-300x152.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/06105430/Screenshot-164-768x388.png 768w" alt="" width="997" height="504" /></a>
4. 에퀴닉스 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EQIX#NASDAQ">EQIX</a>): 이 데이터 센터 회사는 이번 주에 주가가 소폭 상승하면서 투자자들의 강한 관심을 보였다. 이 회사는 완료된 두 가지 제안에 걸쳐 7억 5천만 달러 규모의 그린 본드를 발행했다고 <a href="https://investor.equinix.com/news-events/press-releases/detail/1051/equinix-issues-more-than-750-million-in-green-bonds-to">발표</a>했다. 이 그린 본드는 회사의 지속 가능성 이니셔티브를 지원하는 데 사용된다.
&#8220;그린 본드는 자금을 확보하고 당사 운영의 지속 가능성을 향상시키는 중요한 이니셔티브를 지원하는 귀중한 수단이다&#8221;라고 에퀴닉스의 기업 금융 및 지속 가능성 SVP인 카트리나 라이밀(Katrina Rymill)이 말했다. &#8220;지난 5년 동안 우리의 그린 본드는 105개 현장에서 172개의 녹색 건물 프로젝트, 33개의 에너지 효율 프로젝트, 2개의 전력 구매 계약 프로젝트에 자금을 지원했다.&#8221;
이 새로운 그린 본드는 회사가 S&amp;P 500 기업 중 가장 긴 연속 기록인 86분기 연속 매출 성장을 지원하기 위한 새로운 노력에 계속 투자하는 데 도움이 될 수 있다.
금요일 이 회사의 주식은 0.46% 하락한 817.96달러에 마감되었다.
<figure class="wp-block-image size-full"><a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent090624&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" class="wp-image-534850" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/06105452/Screenshot-165.png" sizes="(max-width: 995px) 100vw, 995px" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/06105452/Screenshot-165.png 995w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/06105452/Screenshot-165-300x151.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/06105452/Screenshot-165-768x387.png 768w" alt="" width="995" height="502" /></a></figure>
5. 테논 메디컬 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TNON#NASDAQ">TNON</a>): 두 가지 <a href="https://ir.tenonmed.com/">소식</a> 덕분에 이번 주 동안 이 의료기기 회사에 대한 투자자의 관심이 높아졌다. 이 회사는 9월 4일 1:8 역주식 분할을 발표했으며 이는 9월 6일부터 시행되었다. 역주식 분할은 회사의 유동 주식수와 발행 주식수를 줄이므로 소매 투자자들의 관심을 끄는 경우가 많다.
테논은 또한 카타마란 SI 관절 시스템(Catamaran SI Joint Fusion System)에 대한 종동업계 검토 간행물을 발표했다. 이 동종업계 검토 결과, 시술 후 12개월이 지난 시점에 유합의 증거가 나타났다고 회사측이 밝혔다.
이 회사의 주식은 금요일 18.82% 하락한 3.92달러에 마감되었다. 이후 시간외 거래에서 7.34% 추가 하락했다.
<figure class="wp-block-image size-full"><a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent090624&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" class="wp-image-534851" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/06105510/Screenshot-166.png" sizes="(max-width: 991px) 100vw, 991px" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/06105510/Screenshot-166.png 991w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/06105510/Screenshot-166-300x152.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/06105510/Screenshot-166-768x389.png 768w" alt="" width="991" height="502" /></a></figure>
다음 주 보고서를 기대해 주시고, 최신 헤드라인과 <a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent090624&amp;t=be2bearmibe3na1" target="_blank" rel="noreferrer noopener">주요 시장 동향 뉴스를 여기서 확인하세요.</a>
최신 스톡 위스퍼 지수 보고서를 여기에서 읽어보세요:
<ul>
<li><a href="https://www.benzinga.com/top-stories/24/08/40284758/benzingas-stock-whisper-index-5-stocks-investors-secretly-monitor-but-dont-talk-about-yet" target="_blank" rel="noreferrer noopener">8월 9일</a></li>
<li><a href="https://www.benzinga.com/general/biotech/24/08/40420145/benzingas-stock-whisper-index-5-stocks-investors-secretly-monitor-but-dont-talk-about-yet" target="_blank" rel="noreferrer noopener">8월 16일</a></li>
<li><a href="https://www.benzinga.com/top-stories/24/08/40531771/benzingas-stock-whisper-index-5-stocks-investors-secretly-monitor-but-dont-talk-about-yet" target="_blank" rel="noreferrer noopener">8월 23일</a></li>
<li><a href="https://www.benzinga.com/exclusives/24/08/40653930/benzingas-stock-whisper-index-5-stocks-investors-secretly-monitor-but-dont-talk-about-yet">8월 30일</a></li>
</ul>
다음 읽기: 
<ul>
<li><a href="https://www.benzinga.com/news/earnings/24/09/40748240/how-to-earn-500-a-month-from-oracle-stock-ahead-of-q1-earnings">오라클 주식으로 월 500달러를 버는 방법</a></li>
</ul>
Benzinga Pro의 독점 뉴스 및 도구로 더 많은 승리를 거두세요 
독점 속보 및 스캐너와 같은 Benzinga Pro의 강력한 도구 세트로 다른 트레이더보다 우위를 점하세요. 
<a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor" target="_blank" rel="noreferrer noopener">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

벤징가의 '스톡 위스퍼' 지수: 투자자들이 몰래 주시하지만 아직 말하지 않는 주식 5종목

Comments

Tenon Medical

뉴스

에 대한 최신 뉴스 Tenon Medical (NASDAQ:TNON) 주식

수요일, 10월 02, 2024

토요일, 9월 07, 2024

사람들이 또한 지켜본다

뉴스

파트너 / 기고자

벤징가 글로벌